文献速递妇产影像儿科影像技术与安全US

超声指征侵入性产前诊断的人群趋势:1994年至2016年二十年变迁

Population-based trends in invasive prenatal diagnosis for ultrasound-based indications: two decades of change from 1994 to 2016.
PubMed 文献 · Ultrasound Obstet Gynecol · 2019-01-01

该研究回顾性分析澳大利亚维多利亚州1994至2016年所有超声指征的侵入性产前诊断,共16 152例操作、1 533 317例出生。近年超声异常成为最常见指征(2013至2016年占29.4%),2016年超过95%的操作采用染色体微阵列分析(CMA),致病性拷贝数变异(CNV)最常见(3.5%),其次为21三体(2.8%)。小于16周操作的诊断率显著高于20周后(31.5% vs 9.0%)。

要点

  • 近年超声异常已成为侵入性产前诊断最常见指征,2013至2016年占29.4%。
  • 2016年超过95%的超声指征操作采用CMA,致病性CNV(3.5%)检出率高于21三体(2.8%)。
  • 小于16周超声指征操作的诊断率显著高于20周后(31.5% vs 9.0%)。

核心结论

  • 基因组时代超声指征侵入性产前诊断正以新方式贡献于产前诊断,致病性CNV已成为超声指征检测后最可能的诊断,而非21三体或其他整倍体异常;尽管早孕期非整倍体筛查持续改进,20周后超声指征检测的诊断率因CMA使用增加而保持稳定;小于16周因结构异常进行的操作诊断率最高,支持在11至13周进行早期胎儿结构评估的获益。

研究设计与样本

  • 回顾性分析1994至2016年澳大利亚维多利亚州所有超声指征的侵入性产前诊断(羊膜腔穿刺和绒毛膜绒毛取样),共1 533 317例出生、16 152例操作;获取母亲年龄、检测指征、操作类型、孕龄、染色体分析类型(G显带核型分析或染色体微阵列分析(CMA))及检测结果;采用χ2检验分析趋势或比例差异。

诊断标准与关键数值

  • 超声指征包括胎儿结构异常、胎儿死亡、胎儿生长受限、羊水量异常、遗传「软指标」和未明确的超声异常;诊断率定义为检出主要异常的检测百分比,按年份、母亲年龄和孕龄分析;2016年超过95%的超声指征操作采用CMA,致病性CNV最常见(3.5%),其次为21三体(2.8%);小于16周超声指征检测的诊断率显著高于20周后(31.5% vs 9.0%)。

临床应用与阅片要点

  • 超声异常已成为侵入性产前诊断最常见指征(2013至2016年占29.4%),因其他指征如早孕期联合筛查阳性或单纯高龄的检测陡降;2016年超声指征操作中超过95%采用CMA;小于16周因结构异常进行的操作诊断率最高,支持在11至13周进行早期胎儿结构评估的获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess trends in ultrasound-indicated prenatal diagnostic testing performed over the past two decades in the Australian state of Victoria, in the context of rapidly changing practices in aneuploidy screening and chromosome analysis.

METHODS: This was a retrospective analysis of all ultrasound-indicated prenatal diagnostic testing (amniocentesis and chorionic villus sampling) performed in the state of Victoria between 1994 and 2016. Ultrasound indications for testing included: fetal structural abnormality, fetal death, fetal growth restriction, abnormal amniotic fluid volume, genetic 'soft marker' and unspecified ultrasound abnormality. Maternal age, indication for testing, type of diagnostic procedure, gestational age, type of chromosome analysis (G-banded karyotyping or chromosomal microarray (CMA)) and test results were obtained. Diagnostic yield (i.e. percentage of tests yielding a major abnormality) was analyzed by year, maternal age and gestational age. Statistical analysis was performed using the χ2 tests for trend or difference in proportions, as appropriate.

RESULTS: During the 23-year study period, 1 533 317 births were recorded and 16 152 diagnostic procedures were performed for the primary indication of ultrasound abnormality. In recent years, ultrasound abnormality became the most common indication for prenatal invasive testing (29.4% of diagnostic tests between 2013 and 2016) due to a steep decline in testing for other indications such as positive result on combined first-trimester screening or advanced maternal age alone. In 2016, over 95% of ultrasound-indicated procedures were performed with CMA; among these, pathogenic copy number variant (CNV) was the most common (3.5%) abnormality detected, followed by trisomy 21 (2.8%). The diagnostic yield of ultrasound-indicated tests performed < 16 weeks was significantly higher than that of tests performed after 20 weeks (31.5% vs 9.0%).

CONCLUSIONS: Ultrasound-indicated invasive testing is contributing to prenatal diagnosis in new ways in the genomic era. A pathogenic CNV is now the most likely diagnosis after ultrasound-indicated testing, rather than trisomy 21 or other whole-chromosome aneuploidy. Despite steady improvements in first-trimester screening for aneuploidy, the diagnostic yield of ultrasound-indicated tests > 20 weeks has remained stable due to increased utilization of CMA. Procedures performed for structural abnormalities < 16 weeks continue to have the highest diagnostic yield, supporting the benefits of early fetal structural assessment at 11-13 weeks. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lostchuck E, Poulton A, Halliday J, et al. Population-based trends in invasive prenatal diagnosis for ultrasound-based indications: two decades of change from 1994 to 2016. Ultrasound Obstet Gynecol. 2019. PMID: 29877030. doi:10.1002/uog.19107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。